Cleared Traditional

K870790 - REFLECTIVE MIRROR/CO2 LASER SURG CAT. #902002-000 (FDA 510(k) Clearance)

Class I General & Plastic Surgery device.

K870790 · Lifestream Int'L, Inc. · General & Plastic Surgery device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 1987
Decision
34d
Days
Class 1
Risk

K870790 is an FDA 510(k) clearance for the REFLECTIVE MIRROR/CO2 LASER SURG CAT. #902002-000. Classified as Mirror, General & Plastic Surgery (product code FTX), Class I - General Controls.

Submitted by Lifestream Int'L, Inc. (Houston, US). The FDA issued a Cleared decision on April 1, 1987 after a review of 34 days - a notably fast clearance cycle.

This device falls under the General & Plastic Surgery FDA review panel, regulated under 21 CFR 878.4800 - the FDA general and plastic surgery device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Lifestream Int'L, Inc. devices

Submission Details

510(k) Number K870790 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 26, 1987
Decision Date April 01, 1987
Days to Decision 34 days
Submission Type Traditional
Review Panel General & Plastic Surgery (SU)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
80d faster than avg
Panel avg: 114d · This submission: 34d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FTX Mirror, General & Plastic Surgery
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 878.4800
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.